Literature DB >> 7746777

Late cardiac effects after treatment for childhood Hodgkin's disease with chemotherapy and low-dose radiotherapy.

I Ilhan1, F Sarialioglu, N Ozbarlas, M Büyükpamukçu, C Akyüz, T Kutluk.   

Abstract

Twenty-four patients under 18 years when treated for Hodgkin's disease (20 male, four female) were examined no less than five years after the completion of the treatment. The mean age was 17 years (range 9.5-25.0 years) at the time of study. All patients received six courses of cyclophosphamide-oncovin-procarbazine-prednisolone chemotherapy; in addition, nine patients received low-dose radiotherapy excluding the mediastinum and eight of 24 patients received mediastinal radiotherapy; the dose was between 20-30 Gy. All patients had normal cardiovascular findings on clinical examination. ECG and chest radiography were within normal limits in all patients. Resting left ventricular ejection fraction and fractional shortening were decreased in only one patient (4%), but there was no significant difference between the patient group and a control group for left ventricular systolic function (p > 0.05). In the patient group, early diastolic peak velocity, peak velocity at atrial contraction, left ventricular isovolumic relaxation time, and the rate of decrease of flow velocity in early diastole were significantly different from that of the control group (p < 0.05). In conclusion, the late effects of our treatment protocol for Hodgkin's disease appear to be minimal. These observations support combined modality, low-dose irradiation regimens in children and adolescents and suggest the need for careful cardiac screening of treated patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7746777      PMCID: PMC2398159          DOI: 10.1136/pgmj.71.833.164

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  13 in total

1.  Coronary heart disease after mediastinal irradiation for Hodgkin's disease.

Authors:  R A McReynolds; G L Gold; W C Roberts
Journal:  Am J Med       Date:  1976-01       Impact factor: 4.965

2.  Pediatric Hodgkin's disease: pulmonary, cardiac, and thyroid function following combined modality therapy.

Authors:  J M Mefferd; S S Donaldson; M P Link
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-03       Impact factor: 7.038

3.  Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin's disease.

Authors:  S Pohjola-Sintonen; K J Tötterman; M Salmo; P Siltanen
Journal:  Cancer       Date:  1987-07-01       Impact factor: 6.860

4.  Cardiac disease following treatment of Hodgkin's disease in children and adolescents.

Authors:  S L Hancock; S S Donaldson; R T Hoppe
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

Review 5.  Radiation-induced heart disease: an update.

Authors:  J R Stewart; L F Fajardo
Journal:  Prog Cardiovasc Dis       Date:  1984 Nov-Dec       Impact factor: 8.194

6.  Acute myocardial infarction with normal coronary arteriogram after mantle field radiation therapy for Hodgkin's disease.

Authors:  J Yahalom; Y Hasin; Z Fuks
Journal:  Cancer       Date:  1983-08-15       Impact factor: 6.860

7.  Detection of radiation cardiomyopathy by gated radionuclide angiography.

Authors:  R J Burns; B Z Bar-Shlomo; M N Druck; J G Herman; B W Gilbert; D J Perrault; P R McLaughlin
Journal:  Am J Med       Date:  1983-02       Impact factor: 4.965

8.  Late cardiac effects of therapeutic mediastinal irradiation. Assessment by echocardiography and radionuclide angiography.

Authors:  J S Gottdiener; M J Katin; J S Borer; S L Bacharach; M V Green
Journal:  N Engl J Med       Date:  1983-03-10       Impact factor: 91.245

9.  Delayed pericardial disease after radiotherapy.

Authors:  M M Applefeld; R G Slawson; M Hall-Craigs; D C Green; R T Singleton; P H Wiernik
Journal:  Am J Cardiol       Date:  1981-02       Impact factor: 2.778

10.  Long-term cardiac sequelae after treatment of malignant tumors with radiotherapy or cytostatics in childhood.

Authors:  L Mäkinen; A Mäkipernaa; J Rautonen; M Heino; S Pyrhönen; L A Laitinen; M A Siimes
Journal:  Cancer       Date:  1990-05-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.